See the DrugPatentWatch profile for Busulfan
What “busulfan protocol” clinical trials usually study
Busulfan is an alkylating chemotherapy drug used in conditioning regimens before hematopoietic stem cell transplant (HSCT). Clinical trials that refer to a “busulfan protocol” typically test one of these components: the conditioning schedule (dose and timing), how busulfan is monitored/adjusted (often via blood-level–based dosing), and how the regimen compares against other conditioning approaches in terms of transplant outcomes and toxicity [1].
Which clinical trial protocols are most commonly seen (dose levels and monitoring)
Most busulfan protocol trials focus on optimizing exposure to reduce toxicity while maintaining efficacy. In many settings this means using therapeutic drug monitoring (TDM) to target busulfan exposure and adjust dosing based on measured levels, rather than using a fixed dose for all patients [1][2].
How long do busulfan conditioning trials usually take from enrollment to results
Timeline varies by trial design and endpoints, but HSCT conditioning trials often have:
- An acute phase around conditioning and transplant (days)
- Follow-up for engraftment and short-term toxicities (weeks to a few months)
- Longer follow-up for relapse, survival, and late effects (often 1–5+ years) [1][2]
What endpoints these trials typically measure
Common trial endpoints for busulfan conditioning protocols include engraftment success, rates of transplant-related complications (like regimen-related toxicity), overall survival and disease-free survival, relapse/progression, graft-versus-host disease (GVHD) outcomes, and regimen-related mortality. Many trials also report toxicity rates and whether TDM changes exposure distributions and adverse-event profiles [1][2].
Common patient populations studied
Busulfan-based protocols are usually tested in transplant populations such as:
- Patients undergoing allogeneic HSCT (often for hematologic malignancies or marrow failure)
- Patients receiving autologous HSCT in specific conditioning contexts
Eligibility depends on the specific protocol and disease setting [1].
Risks patients ask about in busulfan protocol trials
Patients and clinicians often pay close attention to:
- Regimen-related toxicity during the conditioning window
- Toxicities that can be influenced by busulfan exposure (which is one reason TDM-based protocols are studied) [1][2]
- GVHD and transplant complications in the months after HSCT [1]
How to find a specific “busulfan protocol” trial (so you get the exact regimen)
Because “busulfan protocol clinical trial” can refer to different regimens (different doses/schedules, TDM vs fixed dosing, conditioning combinations, and transplant types), the most reliable way to identify the exact trial is to search by:
- Condition being treated (e.g., leukemia, lymphoma, marrow failure)
- Transplant type (allogeneic vs autologous)
- Whether the protocol uses pharmacokinetic monitoring/TDM
- Institution/country and year
If you share any extra detail you have (trial ID, disease, transplant type, or the exact wording of the protocol), I can help pinpoint the right study.
Sources
- https://pmc.ncbi.nlm.nih.gov/articles/PMC10219403/
- https://pubmed.ncbi.nlm.nih.gov/ (busulfan therapeutic drug monitoring and conditioning regimen literature; use search terms “busulfan therapeutic drug monitoring trial conditioning regimen”)